Clinical Trial Update: A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of volociximab in combination with gemcitabine for metastatic pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Volociximab (volociximab)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED